Quantitative multimodal multiparametric imaging in Alzheimer’s disease

Qian Zhao, Xueqi Chen, Yun Zhou

Research output: Contribution to journalArticle

Abstract

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, causing changes in memory, thinking, and other dysfunction of brain functions. More and more people are suffering from the disease. Early neuroimaging techniques of AD are needed to develop. This review provides a preliminary summary of the various neuroimaging techniques that have been explored for in vivo imaging of AD. Recent advances in magnetic resonance (MR) techniques, such as functional MR imaging (fMRI) and diffusion MRI, give opportunities to display not only anatomy and atrophy of the medial temporal lobe, but also at microstructural alterations or perfusion disturbance within the AD lesions. Positron emission tomography (PET) imaging has become the subject of intense research for the diagnosis and facilitation of drug development of AD in both animal models and human trials due to its non-invasive and translational characteristic. Fluorodeoxyglucose (FDG) PET and amyloid PET are applied in clinics and research departments. Amyloid beta (Aβ) imaging using PET has been recognized as one of the most important methods for the early diagnosis of AD, and numerous candidate compounds have been tested for Aβ imaging. Besides in vivo imaging method, a lot of ex vivo modalities are being used in the AD researches. Multiphoton laser scanning microscopy, neuroimaging of metals, and several metal bioimaging methods are also mentioned here. More and more multimodality and multiparametric neuroimaging techniques should improve our understanding of brain function and open new insights into the pathophysiology of AD. We expect exciting results will emerge from new neuroimaging applications that will provide scientific and medical benefits.

Original languageEnglish (US)
Pages (from-to)29-37
Number of pages9
JournalBrain Informatics
Volume3
Issue number1
DOIs
StatePublished - Mar 1 2016

Fingerprint

Multimodal Imaging
Alzheimer Disease
Neuroimaging
Imaging techniques
Positron emission tomography
Positron-Emission Tomography
Amyloid
Metals
Brain
Research
Diffusion Magnetic Resonance Imaging
Temporal Lobe
Confocal Microscopy
Neurodegenerative Diseases
Magnetic resonance
Atrophy
Early Diagnosis
Anatomy
Magnetic resonance imaging
Magnetic Resonance Spectroscopy

Keywords

  • Alzheimer’s disease
  • Amyloid beta
  • MRI
  • Multimodal
  • Neuroimaging
  • PET

ASJC Scopus subject areas

  • Neurology
  • Computer Science Applications
  • Cognitive Neuroscience

Cite this

Quantitative multimodal multiparametric imaging in Alzheimer’s disease. / Zhao, Qian; Chen, Xueqi; Zhou, Yun.

In: Brain Informatics, Vol. 3, No. 1, 01.03.2016, p. 29-37.

Research output: Contribution to journalArticle

Zhao, Qian ; Chen, Xueqi ; Zhou, Yun. / Quantitative multimodal multiparametric imaging in Alzheimer’s disease. In: Brain Informatics. 2016 ; Vol. 3, No. 1. pp. 29-37.
@article{fc3e4e455a334d6eb77f5ac0476e6e66,
title = "Quantitative multimodal multiparametric imaging in Alzheimer’s disease",
abstract = "Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, causing changes in memory, thinking, and other dysfunction of brain functions. More and more people are suffering from the disease. Early neuroimaging techniques of AD are needed to develop. This review provides a preliminary summary of the various neuroimaging techniques that have been explored for in vivo imaging of AD. Recent advances in magnetic resonance (MR) techniques, such as functional MR imaging (fMRI) and diffusion MRI, give opportunities to display not only anatomy and atrophy of the medial temporal lobe, but also at microstructural alterations or perfusion disturbance within the AD lesions. Positron emission tomography (PET) imaging has become the subject of intense research for the diagnosis and facilitation of drug development of AD in both animal models and human trials due to its non-invasive and translational characteristic. Fluorodeoxyglucose (FDG) PET and amyloid PET are applied in clinics and research departments. Amyloid beta (Aβ) imaging using PET has been recognized as one of the most important methods for the early diagnosis of AD, and numerous candidate compounds have been tested for Aβ imaging. Besides in vivo imaging method, a lot of ex vivo modalities are being used in the AD researches. Multiphoton laser scanning microscopy, neuroimaging of metals, and several metal bioimaging methods are also mentioned here. More and more multimodality and multiparametric neuroimaging techniques should improve our understanding of brain function and open new insights into the pathophysiology of AD. We expect exciting results will emerge from new neuroimaging applications that will provide scientific and medical benefits.",
keywords = "Alzheimer’s disease, Amyloid beta, MRI, Multimodal, Neuroimaging, PET",
author = "Qian Zhao and Xueqi Chen and Yun Zhou",
year = "2016",
month = "3",
day = "1",
doi = "10.1007/s40708-015-0028-9",
language = "English (US)",
volume = "3",
pages = "29--37",
journal = "Brain Informatics",
issn = "2198-4018",
publisher = "Springer Berlin",
number = "1",

}

TY - JOUR

T1 - Quantitative multimodal multiparametric imaging in Alzheimer’s disease

AU - Zhao, Qian

AU - Chen, Xueqi

AU - Zhou, Yun

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, causing changes in memory, thinking, and other dysfunction of brain functions. More and more people are suffering from the disease. Early neuroimaging techniques of AD are needed to develop. This review provides a preliminary summary of the various neuroimaging techniques that have been explored for in vivo imaging of AD. Recent advances in magnetic resonance (MR) techniques, such as functional MR imaging (fMRI) and diffusion MRI, give opportunities to display not only anatomy and atrophy of the medial temporal lobe, but also at microstructural alterations or perfusion disturbance within the AD lesions. Positron emission tomography (PET) imaging has become the subject of intense research for the diagnosis and facilitation of drug development of AD in both animal models and human trials due to its non-invasive and translational characteristic. Fluorodeoxyglucose (FDG) PET and amyloid PET are applied in clinics and research departments. Amyloid beta (Aβ) imaging using PET has been recognized as one of the most important methods for the early diagnosis of AD, and numerous candidate compounds have been tested for Aβ imaging. Besides in vivo imaging method, a lot of ex vivo modalities are being used in the AD researches. Multiphoton laser scanning microscopy, neuroimaging of metals, and several metal bioimaging methods are also mentioned here. More and more multimodality and multiparametric neuroimaging techniques should improve our understanding of brain function and open new insights into the pathophysiology of AD. We expect exciting results will emerge from new neuroimaging applications that will provide scientific and medical benefits.

AB - Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, causing changes in memory, thinking, and other dysfunction of brain functions. More and more people are suffering from the disease. Early neuroimaging techniques of AD are needed to develop. This review provides a preliminary summary of the various neuroimaging techniques that have been explored for in vivo imaging of AD. Recent advances in magnetic resonance (MR) techniques, such as functional MR imaging (fMRI) and diffusion MRI, give opportunities to display not only anatomy and atrophy of the medial temporal lobe, but also at microstructural alterations or perfusion disturbance within the AD lesions. Positron emission tomography (PET) imaging has become the subject of intense research for the diagnosis and facilitation of drug development of AD in both animal models and human trials due to its non-invasive and translational characteristic. Fluorodeoxyglucose (FDG) PET and amyloid PET are applied in clinics and research departments. Amyloid beta (Aβ) imaging using PET has been recognized as one of the most important methods for the early diagnosis of AD, and numerous candidate compounds have been tested for Aβ imaging. Besides in vivo imaging method, a lot of ex vivo modalities are being used in the AD researches. Multiphoton laser scanning microscopy, neuroimaging of metals, and several metal bioimaging methods are also mentioned here. More and more multimodality and multiparametric neuroimaging techniques should improve our understanding of brain function and open new insights into the pathophysiology of AD. We expect exciting results will emerge from new neuroimaging applications that will provide scientific and medical benefits.

KW - Alzheimer’s disease

KW - Amyloid beta

KW - MRI

KW - Multimodal

KW - Neuroimaging

KW - PET

UR - http://www.scopus.com/inward/record.url?scp=85026346603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026346603&partnerID=8YFLogxK

U2 - 10.1007/s40708-015-0028-9

DO - 10.1007/s40708-015-0028-9

M3 - Article

VL - 3

SP - 29

EP - 37

JO - Brain Informatics

JF - Brain Informatics

SN - 2198-4018

IS - 1

ER -